论文部分内容阅读
研究复方硫酸长春新碱、盐酸米托蒽醌脂质体(Liposome carried with vincristine and mitoxantrone,VCR-MTO-LP)对荷MCF-7人乳腺癌裸鼠的疗效和毒性。经荷瘤裸鼠尾静脉注射给药,测定各组荷瘤裸鼠抑瘤率和肿瘤体积生长曲线;做荷瘤裸鼠的骨髓涂片;观察荷瘤裸鼠给药局部的刺激性以及绘制平均体重随时间的变化曲线。VCR-MTO-LP组的抑瘤率为67.13%,VCR-MTO-Soln组的抑瘤率为67.75%,抑瘤率均高于其它给单一药物给药组;VCR-MTO-Soln组所检测的3只荷瘤裸鼠的骨髓涂片中有2只发生骨髓抑制的药物毒副反应,其余各组骨髓涂片结果为骨髓增生活跃,未发生骨髓抑制;注射局部组织观察结果为脂药物组裸鼠尾部组织受损、坏死。体重变化曲线为脂质体组体重增重高于所对应的药物组。VCR和MTO联合用药可提高对荷MCF-7人乳腺癌裸鼠的抑瘤率;VCR-MTO-LP组的抑瘤率与对照VCR-MTO-Soln组无明显差异,但以脂质体作为药物载体,可减免药物对于荷瘤裸鼠的毒副作用,该研究为脂质体可作为复方抗癌药物载体提供了依据。
To investigate the curative effect and toxicity of compound vincristine sulfate and mitoxantrone (VCR-MTO-LP) on nude mice bearing MCF-7 breast cancer. The tumor-bearing nude mice were injected intravenously via the tail vein to determine the growth inhibition rate and tumor volume growth curve of the nude mice in each group. The bone marrow smears of the nude mice bearing the tumor were observed. Average body weight with time curve. The anti-tumor rate of VCR-MTO-Soln group was 67.13%, the anti-tumor rate of VCR-MTO-Soln group was 67.75% Of the three tumor-bearing nude mice bone marrow smear in 2 cases of bone marrow suppression drug toxicity, the rest of the group of bone marrow smear results for bone marrow hyperplasia, did not occur bone marrow suppression; injection of local tissue observation results for the lipid drug group Nude mice tail tissue damage, necrosis. Body weight curve for the liposome weight gain was higher than the corresponding drug group. The combination of VCR and MTO could increase the tumor inhibition rate of MCF-7 human breast cancer nude mice. The tumor inhibition rate of VCR-MTO-LP group was not significantly different from that of control VCR-MTO-Soln group. However, Drug carrier, can reduce the drug side effects on tumor-bearing nude mice, the study provides a basis for the liposome can be used as a compound carrier for anticancer drugs.